Fibrin aggregation and clotting

Fibrin Glue (porcine)

1 Kit 195 € available

Art. No. F007
Background info Biological two component glue from porcine plasma
Source Porcine plasma
Description Fibrin Glue is a natural product consisting of two components: Fibrinogen concentrate and thrombin. After mixing both components, polymerization of fibrin occurs resulting in an elastic and opaque fibrin matrix. During polymerization, thrombin sequentially cleaves off the fibrinopeptides A and B from fibrinogen, which normally prevent spontaneous polymerization. The result is a three-dimensional network of branching fibres that form hydrogels with large elastic moduli at very low fraction of polymer.
Reagents in the kit Component 1 (F017, Fibrinogen Conc., porcine): Frozen viscous liquid (flakes), salmon colour
Component 2 (F027, Thrombin, porcine): Frozen liquid, translucent
Application A fibrin clot is a network of proteins that is produced naturally by the blood coagulation system after vascular injury. Using purified fibrinogen and thrombin, a fibrin hydrogel can be engineered in vitro and used as a tissue substitute e.g. to simulate wound healing. The scaffold consists of naturally occurring biomaterials composed of a cross-linked network which is biodegradable. Hydrogels formed by fibrin can be manipulated to have various sizes, shapes and stiffness according to the user’s application and needs. Because of these unique properties fibrin hydrogels act as an interface for cells grown on two- or within threedimensional matrices. Additional proteins can be incorporated into fibrin hydrogels, e.g. fibronectin, vitronectin, laminin and collagen, through cross-linking by FXIII. This can be relevant to achieve a controlled release of molecules in many applications, for example in tissue culture.
Working dilutions According to the application, the ratio of component 1 to component 2 can be titrated to form hydrogels of defined shape and stiffness. A ratio of 20:1 (v/v) between component 1 and component 2 should be a useful starting point.
Storage Both components should be stored frozen at -20°C or lower
Related Products F008 - Fibrin Glue (bovine)


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • CELIACHIA 2020

    07.02.2020 - 08.02.2020
    Milan, Italy

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland